Evolution of Blood Safety in Switzerland over the Last 25 Years for HIV, HCV, HBV and Treponema pallidum

During the last few decades, efforts to increase the safety of blood and blood products have mainly focused on preventing the viral infections HCV, HIV, HBV and Treponema pallidum. The evolution of these approaches and the achieved increase in safety is shown for the last 25 years in Switzerland. In...

Full description

Saved in:
Bibliographic Details
Published in:Viruses Vol. 14; no. 12; p. 2611
Main Authors: Niederhauser, Christoph, Tinguely, Caroline, Stolz, Martin, Vock, Michael, El Dusouqui, Soraya Amar, Gowland, Peter
Format: Journal Article
Language:English
Published: Switzerland MDPI AG 23.11.2022
MDPI
Subjects:
Algorithms
Antibodies
Antigens
Bacterial infections
blood
Blood & organ donations
blood donation
Blood Donors
Blood Safety
Blood transfusions
evolution
evolution of the screening strategies
Hepatitis B
Hepatitis B virus - genetics
Hepatitis C
Hepatitis C - epidemiology
HIV
HIV Infections - prevention & control
Human immunodeficiency virus
Humans
Infections
Infectious diseases
Mass Screening - methods
Nucleic Acid Amplification Techniques
nucleic acid amplification technology (NAT)
nucleic acids
pathogens
Safety
safety of labile blood components
Serology
Switzerland
Switzerland - epidemiology
Syphilis
Testing laboratories
Treponema pallidum
Treponema pallidum - genetics
Viruses
Switzerland
nucleic acid amplification technology (NAT)
evolution of the screening strategies
safety of labile blood components
blood donation
ISSN:1999-4915, 1999-4915
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:During the last few decades, efforts to increase the safety of blood and blood products have mainly focused on preventing the viral infections HCV, HIV, HBV and Treponema pallidum. The evolution of these approaches and the achieved increase in safety is shown for the last 25 years in Switzerland. In detail, the prevalences and incidences of the infection disease and the theoretical estimated residual risks (RR) of these blood-borne infections are presented. Prevalences, incidences and, in particular, the RR have decreased considerably over the last 25 years. This was achieved primarily by the adoption of strict criteria for the selection of blood donors, refined questionnaires, the introduction of increasingly sensitive serological screening tests and the implementation of nucleic acid testing (NAT) for these blood-borne pathogens. These NAT assays have significantly shortened the window period between infection and the first detection of the infectious agent in the blood of an infected individual. A form of “real life” comparison or confirmation is provided by the reported lookback procedures (LBP) and the haemovigilance data of the Swiss competent authority, Swissmedic. These data are in agreement, and thus support the very low prevalences, incidences and RR.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1999-4915
1999-4915
DOI:10.3390/v14122611